Morning Brief — Tuesday, August 11, 2026

Market Overview

Equity futures are mixed pre-bell as the US-Iran nuclear stalemate continues to weigh on risk sentiment, with oil elevated and inflation data (CPI) looming as the week’s key macro catalyst. Energy stocks are catching a significant bid on the back of strong oilfield services earnings (NESR, HP, NBR, PTEN), while biotech is lit up on ABCL’s hot-flash trial data. The broader market is in a “wait and see” posture ahead of CPI — retail sentiment has drifted to neutral on SPY and reportedly “extremely bearish” on QQQ, which is actually a contrarian setup for a squeeze higher if inflation prints cool.

Claude’s Call

UP — The CPI anxiety is creating a buy-the-dip setup: sector breadth is surprisingly strong (energy, biotech, tech all participating), earnings beats are outweighing misses this week, and the “extremely bearish” QQQ sentiment is a classic short-squeeze trigger. I expect the S&P 500 to grind higher by 0.3–0.7% as long as CPI doesn’t come in materially hot.

Top Movers

RUSHA (+51.1%) — $80.77 → $91.19 (+12.9% upside) Thesis: This is the single most suspicious move on today’s board — a 51% single-day gain on a commercial truck retailer that in-line met revenue estimates two weeks ago and posted a modest EPS beat of 6.5%. There is no fresh news today explaining this magnitude of move, and with volume ratio at 0.01 (essentially no volume confirmation), this has all the hallmarks of a thin-float gap-and-trap. Rush Enterprises is a cyclical, slow-growth business in a sector where YoY revenues are declining. Price is at 6-month highs with zero SMA-200 data and an SMA-50 at $49.87 — meaning this stock has effectively doubled in a month. This is a trap. Do not chase. Levels: First resistance at fib ext 1.272 of $91.19. Nearest meaningful support is fib 23.6% at $71.13 — a long fall from here. The 50-day SMA at $49.87 is the real floor.

ABCL (+34.8%) — $9.34 → $11.08 (+18.6% upside) Thesis: This is the real deal today. AbCellera’s ABCL635 menopause/hot-flash candidate posted strong Phase data showing a single-dose reduction in hot flash frequency — a massive unmet need in the menopausal women market. The stock is up ~172% YTD and hit a 3-year high intraday. The catalyst is company-specific and clinical — not sector sympathy. That said, ABCL is a pre-revenue antibody discovery platform pivoting to proprietary drugs, and this is still early-stage clinical news. The fib 23.6% support at $7.83 provides a reasonable stop zone if the clinical euphoria fades. Volume ratio at 0.14 is modest but the price action speaks for itself — 52-week high on real news. Levels: Exit target at fib ext 1.272 of $11.08. Hard support at $7.83 (fib 23.6%). Below that, $6.90 (fib 38.2%).

NESR (+23.3%) — $35.79 → $40.33 (+12.7% upside) Thesis: NESR just crossed $2 billion annualized revenue run-rate ahead of schedule, driven by the Jafura ramp-up in Saudi Arabia and initiated its first shareholder return program. This is a legitimate fundamental breakout — an oilfield services company operating in the Middle East/North Africa region that just posted record results and is now at an all-time high. Energy sector tailwinds from elevated oil prices compound the company-specific story. At $35.79 and at 6-month highs with no overhead resistance, this has runway. The Fib ext 1.272 at $40.33 is a clean first target. Levels: Exit at $40.33 (fib ext 1.272), stretch to $46.10 (fib ext 1.618). Support at $31.87 (fib 23.6%). SMA-50 is far below at $27.17 — this has broken out cleanly.

NUTX (+21.9%) — $197.51 → $228.93 (+15.9% upside) Thesis: Nutex Health is a microhospital operator that posted higher Q2 profitability and EBITDA despite a revenue dip, boosted by lower arbitration costs and continued patient volume growth. The RSI at 28 is notably oversold for a stock making a 22% move — this suggests the stock was beaten down hard before today’s bounce. At $197.51 against a 6-month high of $198.58, this is essentially testing all-time 6-month highs. The microhospital model is a structural growth story as emergency-adjacent care takes share from traditional hospitals. However, reimbursement risk is real and the stock carries wide analyst target dispersion. Levels: Exit at fib ext 1.272 of $228.93. Support at $172.25 (fib 23.6%) and $155.96 (fib 38.2%). SMA-50 at $158.21 is the line-in-the-sand stop.

FSLY (+20.9%) — $27.75 → $40.08 (+44.4% upside) Thesis: Fastly posted record Q2 revenue (+23% YoY), raised full-year guidance, expanded margins to record levels, and is now getting love at the KeyBanc Technology Leadership Forum. The security portfolio expansion and AI/CDN demand narrative is real. Two analysts raised price targets post-earnings and recommended buying the dip — and now the dip is getting bought hard. That said, FSLY trades at 47x forward P/E vs. a peer median of 13.5x — it’s expensive. The valuation is only defensible if 23%+ revenue growth accelerates further. Currently sitting just below its 6-month 23.6% fib support at $27.79, which has flipped to near-term resistance. If it holds above $27.57, next target is the fib ext at $40.08. Levels: Exit at $40.08 (fib ext 1.272). Immediate support at $24.26 (fib 38.2%) and SMA-50 at $20.02.

CLMT (+15.2%) — $45.47 → $52.81 (+16.1% upside) Thesis: Calumet bounced hard after plunging Friday on a surprise net loss. The Q2 results were actually mixed — adjusted EBITDA reached $175M with Specialties segment more than doubling, and Montana Renewables is ramping for future growth. Friday’s selloff looks overdone; the specialties business is genuinely improving. RSI at 16.93 is deeply oversold — this is a classic oversold bounce. The risk is that the GAAP net loss reflects real structural cash burn and the bounce is a dead-cat. Montana Renewables remains a long-term optionality play if the renewable fuel credit environment stabilizes. Levels: Exit at $52.81 (fib ext 1.272). Support at $41.98 (fib 23.6%) and $38.87 (fib 38.2%). SMA-50 at $38.44.

NIQ (+21.1%) — $14.14 → $15.64 (+10.6% upside) Thesis: NIQ Global Intelligence delivered its fifth consecutive quarter of beating the top end of guidance — 5.8% organic constant-currency revenue growth, +21.9% adjusted EBITDA, and 270bps of margin expansion to 23.3%. Full-year guidance was raised across all key metrics. This is a steady, compounding market intelligence business executing well. The move to 6-month highs on a solid beat-and-raise is justified. Not a rocket ship, but a quality compounder that was overlooked. Levels: Exit at $15.64 (fib ext 1.272), stretch to $17.73 (fib ext 1.618). Support at $12.58 (fib 23.6%). SMA-50 at $9.99.

HP (+12.9%) — $41.87 → $44.95 (+7.4% upside) Thesis: Helmerich & Payne just secured a long-term FlexRig contract in Australia’s Beetaloo Basin — drilling capacity locked through the next decade — while Q3 results exceeded guidance across all three segments. U.S. drilling rebound plus international wins plus a performance-bonus tailwind from offshore. The 4.7% revenue beat shows real operational momentum. Valuation analysis suggests 11% below fair value. Energy sector bid is a tailwind. This is a quality driller at a reasonable entry. Levels: Exit at $44.95 (fib ext 1.272). Support at $39.19 (fib 23.6%) and $37.54 (fib 38.2%). SMA-50 at $35.30.

SE (+9.2%) — $125.39 → $139.60 (+11.3% upside) Thesis: Sea Limited dropped a monster quarter — revenue up 48% YoY — with Shopee, Monee, and Garena all showing momentum. EPS missed slightly but revenue crushes are what matter for a hyper-growth platform. RSI at 21.74 is deeply oversold for a stock that just reported a blowout quarter, suggesting the stock was under pressure heading into earnings and is now being re-rated. Shopee’s e-commerce momentum in Southeast Asia is a durable secular story. At $125.39 vs. analyst target of $141.97, there’s 13% upside to consensus. Levels: Exit at analyst target $141.97 / fib ext $139.60. Support at $115.07 (fib 23.6%). SMA-50 at $100.20 is the macro floor.

REPL (+13.4%) — $13.67 → $16.93 (+23.8% upside) Thesis: Replimune just got FDA accelerated approval for Tudriqev (its first commercial drug) for skin cancer — on the third try after two complete response letters. This is a genuine de-risking event. The stock also priced a $150M offering at $12.06 (modest dilution), hit a 52-week high, and is now trading at its 6-month peak. However, the 2027 cash cliff is real — management needs Tudriqev to ramp commercial revenues fast or the 2030 profitability timeline looks optimistic. The RSI at 50 and clean technical breakout from $1.70 six months ago is extraordinary. Levels: Exit at $16.93 (fib ext 1.272), stretch to $21.07 (fib ext 1.618). Support at $10.85 (fib 23.6%). SMA-50 at $10.25.

Headlines to Watch

  • “FRMI lands 15-year, $6.5B TensorWave lease for Project Matador” — This is a transformative contract for a data-center developer that was previously un-tenanted; AI infrastructure demand is real and this validates FRMI’s thesis, though governance concerns from the board resignation remain a live risk.
  • “Sea Limited revenue jumps 48%, Shopee outlook strengthens” — The strongest revenue print from a consumer internet platform in weeks; watch for read-through to emerging market e-commerce peers (MercadoLibre, Grab).
  • “CPI data due this week — retail QQQ sentiment ‘extremely bearish’“ — Contrarian signal for a potential squeeze if inflation prints at or below consensus; this is the single most important macro event for market direction this week.
  • “Intel drops 4% on $15B stock offering” — Massive dilution signal from a cash-stressed legacy chipmaker; negative read-through for the legacy semiconductor complex, while reinforcing the NVDA/AMD AI chip concentration trade.
  • “ABCL635 hot flash data drives stock to 3-year highs” — Opens a multi-billion dollar menopause treatment TAM for a company previously valued as a pure-platform antibody discovery business; re-rating is just beginning if Phase 3 design gets validated.
  • “NESR surpasses $2B annualized run-rate, initiates shareholder returns” — Signals MENA oilfield services hitting an inflection point; watch NBR and PTEN as read-through beneficiaries in drilling services.
  • “Rackspace (RXT) faces securities class action lawsuits after guidance cut” — Despite the AI infrastructure pivot narrative, legal overhang + guidance cuts = avoid; the 394% YTD run has priced in a lot of good news that may not materialize.

Claude’s Top Picks

SE (+9.2% today, +12.5% week) — $125.39 → $139.60 (+11.3% upside) Valuation: No comp data provided, but at 48% revenue growth with a post-earnings RSI of 21.74, the market has been severely underpricing this name — now correcting. Upside: 48% revenue growth, Shopee strengthening, analyst consensus at $141.97 with the stock still trading 13% below that target; re-rating has room to run. Risk: EPS miss signals profitability is still inconsistent; if macro risk-off hits EM names (dollar strengthening), SE gets sold first.

NESR (+23.3% today, +28.8% week) — $35.79 → $40.33 (+12.7% upside) Valuation: No comp data available, but $2B+ run-rate with record EBITDA and fresh shareholder returns program at this price level suggests fair-to-cheap for a Middle East oilfield compounder. Upside: All-time 6-month high with clean technical breakout, record results, ahead-of-schedule milestones, and energy sector bid from elevated oil — three tailwinds converging simultaneously. Risk: MENA geopolitical risk is ever-present; if oil rolls over or regional conflict escalates in a way that disrupts operations, this name gets sold hard.

LFST (+9.8% today, +12.9% week) — $11.90 → $13.44 (+13.0% upside) Valuation: No comp data, but a behavioral health company growing revenue 26% YoY, beating EPS by 32%, and posting record free cash flow is likely undervalued vs. healthcare services peers. Upside: Revenue guidance for Q3 was 2.9% above consensus at $430M midpoint, full-year guidance raised, and RSI at 18.52 means the stock was deeply oversold before this bounce — mean reversion is powerful. Risk: Mental health services is heavily dependent on payer reimbursement rates; any policy-level cuts to outpatient behavioral health reimbursement would be a direct headwind to the model.

REPL (+13.4% today, +14.8% week) — $13.67 → $16.93 (+23.8% upside) Valuation: Screens as CHEAP vs. peers (forward P/E negative but peer median at 14.5x); pre-revenue biotech with first commercial product now on market — valuation re-rating is the entire thesis here. Upside: First commercial drug (Tudriqev) just received FDA approval, $150M offering de-risks the 2027 cash cliff somewhat, and the technical breakout from $1.70 to $13.67 in six months shows the market is aggressively re-pricing the pipeline. Risk: Accelerated approval means confirmatory trial data is still needed; if the Phase 3 doesn’t confirm the benefit, approval could be withdrawn — binary risk remains live.

HPK (+10.0% today, +12.7% week) — $7.92 → $9.87 (+24.6% upside) Valuation: Small-cap E&P with Q2 revenue of $272M (+35.9% YoY) and non-GAAP EPS significantly above estimates — this is cheap on any earnings multiple given the beat magnitude. Upside: 35.9% revenue growth, strong margin rebound, non-GAAP EPS smash, energy sector tailwind from elevated oil, and clean fib ext target at $9.87 with SMA-50 support at $7.31 providing a defined stop. Risk: Six-month net loss of -$45M shows H1 was operationally rocky; if oil prices retreat sharply, the entire E&P space de-rates and HPK’s thin margins get squeezed first.

Avoid

RUSHA — 51% single-day gain with 0.01 volume ratio on no fresh news is a textbook thin-float manipulation; the SMA-50 is $30 below current price and the fundamental story (declining revenues, cyclical truck retail) does not support this move.

FRMI — Despite the real TensorWave lease catalyst, FRMI is up 21% today after already being up 19% last Friday; the governance red flags (director resigned citing lack of board transparency), $375M convertible dilution, and 32% YTD decline before this bounce suggest the smart money is distributing into retail euphoria. Below the 6-month high at $11.79, this is still a speculative pre-revenue data center developer.

ABCL — Great catalyst, but +172% YTD on a platform-stage biotech with -76.3% revenue growth and a negative forward P/E means the risk/reward for new longs at $9.34 is asymmetric to the downside if Phase 3 timelines slip or the menopause TAM enthusiasm cools. The valuation screens as “CHEAP” only because earnings are deeply negative — this is a momentum story, not a value story.

WSB Sentiment Check

RKLB — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Rocket Lab is trading at $76.68, down 49% from its 6-month high of $150.23, currently sitting below its SMA-50 at $87.85, and news of possible Neutron delays is a real fundamental headwind — WSB is buying a falling knife that has already broken every meaningful support level. The fib retracement levels ($114–$128) are far overhead; this is not a bounce setup, it’s capitulation hoping.

HTZ — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Hertz at $2.13 is down 73% from its 6-month high of $7.81 and trading near multi-year lows. The SMA-50 at $2.99 is 40% above current price and every fib support level ($3.92–$6.32) is overhead resistance. WSB loves a brand-name bankruptcy recovery play, but without a concrete catalyst (restructuring resolution, new equity sponsor, debt haircut), this is pure speculation — the setup is not a squeeze, it’s a slow bleed.

ASTS — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — ASTS reported a Q2 EPS miss of -$1.72 and held full-year guidance flat. The stock is at $68.15, down 49% from its 6-month high of $133.09, below the SMA-50 at $75.37, and every fib level is overhead resistance. However, space-based mobile connectivity is a legitimately transformative technology and the analyst target at $80.48 implies 18% upside from here. This is a real company with real satellite deployments — but WSB’s 80% bullish read at this level is chasing yesterday’s thesis at today’s still-expensive price.

MU — WSB says: BULLISH (80% bullish) Claude says: AGREE — Micron is sitting precisely at its fib 38.2% support at $872.77 (current price $872.76 — that’s not a coincidence), which is a textbook technical bounce level after a 28% correction from the $1,213 6-month high. HBM/AI memory demand is structural, SK Hynix’s post-IPO weakness is creating a sector buying opportunity, and the $872 fib level is a well-defined risk/reward entry. This is one of the better-supported WSB calls on the board today.

NVDA — WSB says: BULLISH (80% bullish) Claude says: AGREE — NVDA at $220.40 is sitting just above the fib 23.6% support at $218.83 with the SMA-50 at $206.31 as a backstop. The stock is 6% off its 6-month high of $235.47 with no fundamental deterioration — this is a healthy pullback in the best AI infrastructure name in the market. With the fib ext 1.272 at $254.64 as the next target, the risk/reward is attractive for a 1-2 week hold into continued AI spend visibility. This is a consensus call that is also the right call.

Earnings Scorecard

FRMI (Fermi Inc.) — REPORTED | EPS: -$1.14 | Stock: +21.2% | Catalyst: TensorWave lease The stock reaction is driven by the $6.5B, 15-year TensorWave lease announcement — not the earnings print itself. The -$1.14 EPS is irrelevant pre-revenue; what matters is the lease de-risks the core asset. Reaction is partially justified but governance overhang and dilution risk make this a sell-the-rip for new money.

SE (Sea Limited) — REPORTED | EPS: $2.57 | Stock: +9.2% | Rev +48% YoY Revenue beat is massive; EPS missed vs. expectations. The +9.2% reaction is justified and likely insufficient — 48% revenue growth from Shopee + Monee + Garena at this valuation is a buy-the-dip setup. Analyst target at $141.97 suggests 13% more upside.

JD (JD.com) — REPORTED | EPS: $1.37 | Stock: -4.2% No specific beat/miss data available. The negative reaction in a weak-ish EM/China tape is consistent with the macro backdrop. No fresh catalyst to call this a buy.

CAH (Cardinal Health) — REPORTED | EPS: $6.57 | Stock: +3.4% | 2027 guidance topped forecasts Beat on earnings, 2027 outlook above consensus. The +3.4% move is understated — a medical distributor raising forward guidance in a rate-uncertain environment deserves more. Analyst target at $252.40 suggests there’s still upside. Buy the modest dip.

HIMS (Hims & Hers) — REPORTED | EPS: -$0.09 | Stock: -2.5% Revenue growth came at the cost of weakening cash flow. The negative reaction is justified — a consumer health company growing the top line while burning more cash in a higher-rate environment faces a re-rating risk. Hold/avoid until cash flow turns positive.

SMCI (Super Micro Computer) — REPORTED | EPS: $1.92 | Stock: +2.2% | Analyst target: $37.81 The muted +2.2% move on what appears to be a solid print suggests the market is skeptical of SMCI’s sustainability after accounting/governance issues in prior periods. Reaction is likely insufficient if clean, but investors need to see consecutive clean quarters first.

CAVA (CAVA Group) — REPORTED | EPS: $0.52 | Stock: +1.5% | Analyst target: $91.29 A restaurant concept growing same-store sales in a tough consumer environment deserves a bigger reaction. The +1.5% move is too muted relative to the $0.52 EPS print and $91.29 analyst target — this is a buy-the-dip for growth investors in fast-casual.

LITE (Lumentum) — REPORTED | EPS: $5.69 | Stock: -1.3% | Analyst target: $1,125.93 AI optics stocks cooled into earnings (Coherent -12% pre-print), and LITE’s -1.3% reaction on a strong EPS print is a function of the sector rotation away from optical interconnect names after a big run. The analyst target at $1,125 vs. current price implies massive upside — this is a buy-the-dip if you believe AI data center buildout spending continues.

ASTS (AST SpaceMobile) — REPORTED | EPS: -$1.72 | Stock: +0.1% | Q2 miss, guidance held Miss on EPS with guidance held flat. The near-flat reaction is appropriate — the market is not rewarding or punishing, it’s waiting for concrete satellite deployment milestones before re-rating. Hold, do not add.

CRWV (CoreWeave) — REPORTED | EPS: -$2.72 | Stock: +0.6% | Analyst target: $138.37 Pre-profit hyperscaler GPU cloud company with a $100B backlog. The muted +0.6% reaction says the market wants to see whether revenue actually catches up to the backlog — this is a “prove it” moment. Analyst target at $138.37 vs. current price suggests significant upside if the backlog converts. Watch, not a chase today.

CSCO (Cisco Systems) — REPORTED | EPS: $3.00 | Stock: -0.02% | Analyst target: $132.59 Essentially a non-event reaction on a large-cap stalwart. Analyst target at $132.59 suggests 13-15% upside from current levels — Cisco’s AI networking pivot (security + observability) is under-appreciated. Slow accumulation candidate, not a swing trade.

This brief is prepared for informational purposes. All technical levels are derived from the provided Fibonacci retracement/extension calculations. Trade sizing and risk management remain the responsibility of the individual investor.